Application of iPS cell-derived macrophages to cancer therapy

We established a method to produce a large quantity of myeloid cells from human inducible pluripotent stem cells (iPSCs). When injected intraperitoneally into mice carrying established peritoneal tumors, iPSC-derived myeloid cells (iPS-MCs) efficiently accumulated within neoplastic lesions. The intr...

Full description

Saved in:
Bibliographic Details
Published inOncoimmunology Vol. 3; no. 3; p. e27927
Main Authors Senju, Satoru, Koba, Chihiro, Haruta, Miwa, Matsunaga, Yusuke, Matsumura, Keiko, Haga, Eriko, Sasaki, Yuko, Ikeda, Tokunori, Takamatsu, Koutaro, Nishimura, Yasuharu
Format Journal Article
LanguageEnglish
Published United States Taylor & Francis 2014
Landes Bioscience
Subjects
Author's View
gastric cancer
interferon β
iPS cells
macrophages
pancreatic cancer
peritoneal dissemination
macrophages
pancreatic cancer
gastric cancer
peritoneal dissemination
interferon β
iPS cells
Online AccessGet full text

Cover

More Information
Summary:We established a method to produce a large quantity of myeloid cells from human inducible pluripotent stem cells (iPSCs). When injected intraperitoneally into mice carrying established peritoneal tumors, iPSC-derived myeloid cells (iPS-MCs) efficiently accumulated within neoplastic lesions. The intraperitoneal injection of iPS-MCs expressing interferon β significantly inhibited the growth of human gastric and pancreatic cancers implanted in the peritoneal cavity of immunocompromised mice.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2162-4011
2162-402X
2162-402X
DOI:10.4161/onci.27927